<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039595</url>
  </required_header>
  <id_info>
    <org_study_id>11846</org_study_id>
    <nct_id>NCT03039595</nct_id>
  </id_info>
  <brief_title>Ploidy and Stroma in Early Rectal Cancer</brief_title>
  <official_title>An Observational Study to Correlate the Results of Ploidy and Stroma Analysis With Prognosis in Early Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oxford University Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early rectal cancer can be removed by minimally-invasive surgery, and the standard
      pathological assessment of the removed tumour gives valuable information about how advanced
      the tumour is. This gives an indication of how likely the cancer is to recur, so doctors and
      patient can decide on the most appropriate further treatment and follow-up. However there is
      still much uncertainty in these predictions about recurrence. This study will assess two
      further pathology tests, ploidy and stroma ratio in the tumour, by correlating the results
      with outcome. This will determine whether these two tests provide additional value in
      predicting outcome. If so, clinicians would be better able to advise patients with early
      rectal cancer about their prognosis and further management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early rectal cancer can be removed by minimally-invasive surgery, and the standard
      pathological assessment of the removed tumour gives valuable information about how advanced
      the tumour is. This information is very important in indicating whether the cancer is likely
      to recur, and therefore in advising the patient after surgery whether further treatment is
      advisable, and if not, what is the most appropriate follow-up regime. However there is still
      a lot of uncertainty in these predictions about recurrence of the cancer, and better tests
      are being sought. This study aims to look at two further pathology tests, ploidy and stroma
      ratio in the tumour, and correlate these test results with outcome in patients who have had
      an early rectal cancer removed. This will allow the investigators to assess whether these two
      tests provide additional value in predicting outcome. If so, clinicians would be better able
      to advise patients with early rectal cancer about their prognosis and further management.

      Routine histopathology analysis of a rectal cancer specimen removed at surgery includes
      assessment of tumour size, depth of invasion, vascular, lymphatic and perineural invasion,
      tumour involvement of resection margins and nodal involvement. This information is valuable
      in predicting outcome. For example, predicted rates of local recurrence at 36 months
      following local excision of rectal cancer by transanal endoscopic microsurgery (TEM) based on
      tumour size, depth of invasion and lymphatic invasion have been tabulated. However such
      models are not perfect, and leave room for improvement. Ploidy and stroma ratio are two
      further tests which have shown some promise in predicting outcome.

      Ploidy refers to the number of sets of chromosomes in a cell nucleus. Most human cells are
      normally diploid, with two sets of 23 chromosomes. Abnormal tumour cells may have a different
      number of sets of chromosomes, or be aneuploid, having some replicated or deleted
      chromosomes. In general, aneuploidy in cancer cells is associated with a worse prognosis. An
      early study of DNA ploidy in rectal cancer using flow cytometry showed an independent but
      small predictive effective of aneuploidy on survival. Technological advances now allow more
      accurate and detailed assessment of ploidy. The DNA ploidy status of tumour cells in early
      ovarian cancer has been found to predict which patients will benefit from adjuvant
      chemotherapy after surgery to remove the ovarian tumour and is used routinely in some centres
      to aid in decision-making.

      Stroma ratio refers to the tumour: stroma ratio. A lower proportion of tumour cells or,
      conversely, a higher percentage of stroma, in a cancer tends to be associated with a poorer
      prognosis. This ratio has been found to be strongly associated with tumour growth and
      invasion in colorectal cancers, and to independently predict survival in patients undergoing
      surgery to removal colorectal tumours. However previous studies have looked mainly at more
      advanced colon cancers, rather than early rectal cancers, and have used only cancer-related
      death as the endpoint, rather than looking at local recurrence and response to adjuvant
      treatments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between [A] ploidy status and [B] tumour: stroma ratio with local recurrence of cancer</measure>
    <time_frame>a minimum of 6 months after surgery</time_frame>
    <description>Results of ploidy status and tumour:stromal ratio will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation with local recurrence of the rectal cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between [A] ploidy and [B] stroma analysis with overall survival after TEM surgery to remove rectal cancer</measure>
    <time_frame>a minimum of 6 months after surgery</time_frame>
    <description>Results of ploidy status and tumour:stromal ratio will be correlated with patient follow-up information for between 6 months and 9 years following surgery, to look for any correlation between the test results and overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contribution of [A] ploidy and [B] stroma analysis to a regression model for local recurrence after TEM surgery to remove rectal cancer</measure>
    <time_frame>a minimum of 6 months after surgery</time_frame>
    <description>A regression model will be developed looking at local recurrence of rectal cancer after TEM surgery, and we will assess whether ploidy and stroma are significant variables in this</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis comparing [A] ploidy and [B] stroma results with local recurrence and survival for patients who did and did not receive adjuvant chemo- or radiotherapy</measure>
    <time_frame>a minimum of 6 months after surgery</time_frame>
    <description>A subgroup analysis will correlate local recurrence and survival with the ploidy and stroma test results, in the groups that had and did not have post-operative adjuvant chemo- or radiotherapy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rectal Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ploidy and tumour:stromal ratio measurements</intervention_name>
    <description>Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Specimens of early rectal cancer removed by transanal endoscopic microsurgery, which are
      routinely retained, will be further analysed.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants diagnosed with rectal cancer that is operable and patients who have already
        had rectal cancer removed by transanal endoscopic microsurgery (TEM) in Oxford since 2007.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent (in English) for
             participation in the study, or gave informed consent for donation of tissue for
             research at the time of surgery

          -  Male or Female, aged 18 years or above

          -  Diagnosed with operable rectal cancer

          -  Due to undergo, or has already undergone, TEM surgery to remove rectal cancer

          -  A useable tissue sample has already been, or will be, taken as part of routine surgery

        Exclusion Criteria:

          -  Age less than 18

          -  Adults who are not able to give consent or who are deemed vulnerable

          -  Participants who do not have a useable tissue sample will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Cunningham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Employee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Cunningham, MD</last_name>
    <phone>01865 235657</phone>
    <email>chriscunningham@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helen Jones, MBchB</last_name>
    <phone>01865 235657</phone>
    <email>Helen.jones3@ouh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Cunningham, FRCS MD</last_name>
      <email>chriscunningham@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Bach SP, Hill J, Monson JR, Simson JN, Lane L, Merrie A, Warren B, Mortensen NJ; Association of Coloproctology of Great Britain and Ireland Transanal Endoscopic Microsurgery (TEM) Collaboration. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg. 2009 Mar;96(3):280-90. doi: 10.1002/bjs.6456.</citation>
    <PMID>19224520</PMID>
  </reference>
  <reference>
    <citation>Goh HS, Jass JR, Atkin WS, Cuzick J, Northover JM. Value of flow cytometric determination of ploidy as a guide to prognosis in operable rectal cancer: a multivariate analysis. Int J Colorectal Dis. 1987 Feb;2(1):17-21.</citation>
    <PMID>3598327</PMID>
  </reference>
  <reference>
    <citation>Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Trop√© CG, Danielsen HE. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol. 2003 Oct;14(10):1494-500.</citation>
    <PMID>14504048</PMID>
  </reference>
  <reference>
    <citation>Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol. 2014 Mar;25(3):644-51. doi: 10.1093/annonc/mdt593. Epub 2014 Jan 23.</citation>
    <PMID>24458470</PMID>
  </reference>
  <reference>
    <citation>Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, Kulka J, Pollock S, Rajan SS, Thygesen HH, Hanby AM, Speirs V. The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer. Br J Cancer. 2014 Apr 2;110(7):1744-7. doi: 10.1038/bjc.2014.69. Epub 2014 Feb 18.</citation>
    <PMID>24548861</PMID>
  </reference>
  <reference>
    <citation>West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, Grabsch H. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer. 2010 May 11;102(10):1519-23. doi: 10.1038/sj.bjc.6605674. Epub 2010 Apr 20.</citation>
    <PMID>20407439</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <last_update_submitted>August 13, 2017</last_update_submitted>
  <last_update_submitted_qc>August 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oxford University Hospitals NHS Trust</investigator_affiliation>
    <investigator_full_name>Chris Cunningham</investigator_full_name>
    <investigator_title>Consultant colorectal surgeon</investigator_title>
  </responsible_party>
  <keyword>Early rectal cancer</keyword>
  <keyword>Ploidy</keyword>
  <keyword>Tumour:stroma ratio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual data will be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

